Standard

Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma. / Fominykh, M. S.; Shuvaev, V. A.; Voloshin, S. V.; Schmidt, A. V.; Kuvshinov, A. Y.; Kuzyaeva, A. A.; Zapreeva, I. M.; Abdulkadyrov, K. M.

в: Genes and Cells, Том 9, № 2, 01.01.2014, стр. 38-41.

Результаты исследований: Научные публикации в периодических изданияхстатьяРецензирование

Harvard

Fominykh, MS, Shuvaev, VA, Voloshin, SV, Schmidt, AV, Kuvshinov, AY, Kuzyaeva, AA, Zapreeva, IM & Abdulkadyrov, KM 2014, 'Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma', Genes and Cells, Том. 9, № 2, стр. 38-41.

APA

Fominykh, M. S., Shuvaev, V. A., Voloshin, S. V., Schmidt, A. V., Kuvshinov, A. Y., Kuzyaeva, A. A., Zapreeva, I. M., & Abdulkadyrov, K. M. (2014). Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma. Genes and Cells, 9(2), 38-41.

Vancouver

Fominykh MS, Shuvaev VA, Voloshin SV, Schmidt AV, Kuvshinov AY, Kuzyaeva AA и пр. Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma. Genes and Cells. 2014 Янв. 1;9(2):38-41.

Author

Fominykh, M. S. ; Shuvaev, V. A. ; Voloshin, S. V. ; Schmidt, A. V. ; Kuvshinov, A. Y. ; Kuzyaeva, A. A. ; Zapreeva, I. M. ; Abdulkadyrov, K. M. / Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma. в: Genes and Cells. 2014 ; Том 9, № 2. стр. 38-41.

BibTeX

@article{48fb3e57e47a482da3ce8e691a3f6259,
title = "Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma",
abstract = "High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the one of the effective therapy for patients with multiple myeloma. The aim of our study was to investigate the efficacy and safety of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients. Ten patients with multiple myeloma underwent autologous hematopoietic stem cell transplantation with romiplostim support (romiplostim group). All the patients received 250 μg of the thrombopoietin receptor agonist romiplostim on day of hematopoietic stem cell reinfusion. Thirty patients with multiple myeloma were assessed as a control group (without romiplostim support). The duration of grade 4 thrombocytopenia was 4.0 days for romiplostim group and 7.4 days for the control group (p = 0.003). Time to platelet count >25×109/l was 10.4 days for romiplostim group and 13.0 days for the control group (p = 0.002). Platelet transfusion volume was 980 ml for romiplostim group and 1376 ml for the control group. Safety and efficacy of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients had proven by reduced risk of bleeding and cost minimization.",
keywords = "Autologous stem cell transplantation, High-dose chemotherapy, Multiple myeloma, Romiplostim",
author = "Fominykh, {M. S.} and Shuvaev, {V. A.} and Voloshin, {S. V.} and Schmidt, {A. V.} and Kuvshinov, {A. Y.} and Kuzyaeva, {A. A.} and Zapreeva, {I. M.} and Abdulkadyrov, {K. M.}",
year = "2014",
month = jan,
day = "1",
language = "English",
volume = "9",
pages = "38--41",
journal = "Гены и клетки",
issn = "2313-1829",
publisher = "Институт стволовых клеток человека ",
number = "2",

}

RIS

TY - JOUR

T1 - Efficacy of romiplostim support at autologous stem cell transplantation in patients with multiple myeloma

AU - Fominykh, M. S.

AU - Shuvaev, V. A.

AU - Voloshin, S. V.

AU - Schmidt, A. V.

AU - Kuvshinov, A. Y.

AU - Kuzyaeva, A. A.

AU - Zapreeva, I. M.

AU - Abdulkadyrov, K. M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the one of the effective therapy for patients with multiple myeloma. The aim of our study was to investigate the efficacy and safety of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients. Ten patients with multiple myeloma underwent autologous hematopoietic stem cell transplantation with romiplostim support (romiplostim group). All the patients received 250 μg of the thrombopoietin receptor agonist romiplostim on day of hematopoietic stem cell reinfusion. Thirty patients with multiple myeloma were assessed as a control group (without romiplostim support). The duration of grade 4 thrombocytopenia was 4.0 days for romiplostim group and 7.4 days for the control group (p = 0.003). Time to platelet count >25×109/l was 10.4 days for romiplostim group and 13.0 days for the control group (p = 0.002). Platelet transfusion volume was 980 ml for romiplostim group and 1376 ml for the control group. Safety and efficacy of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients had proven by reduced risk of bleeding and cost minimization.

AB - High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation is the one of the effective therapy for patients with multiple myeloma. The aim of our study was to investigate the efficacy and safety of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients. Ten patients with multiple myeloma underwent autologous hematopoietic stem cell transplantation with romiplostim support (romiplostim group). All the patients received 250 μg of the thrombopoietin receptor agonist romiplostim on day of hematopoietic stem cell reinfusion. Thirty patients with multiple myeloma were assessed as a control group (without romiplostim support). The duration of grade 4 thrombocytopenia was 4.0 days for romiplostim group and 7.4 days for the control group (p = 0.003). Time to platelet count >25×109/l was 10.4 days for romiplostim group and 13.0 days for the control group (p = 0.002). Platelet transfusion volume was 980 ml for romiplostim group and 1376 ml for the control group. Safety and efficacy of romiplostim support at autologous hematopoietic stem cell transplantation in multiple myeloma patients had proven by reduced risk of bleeding and cost minimization.

KW - Autologous stem cell transplantation

KW - High-dose chemotherapy

KW - Multiple myeloma

KW - Romiplostim

UR - http://www.scopus.com/inward/record.url?scp=84926466486&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84926466486

VL - 9

SP - 38

EP - 41

JO - Гены и клетки

JF - Гены и клетки

SN - 2313-1829

IS - 2

ER -

ID: 46138223